University of Florida Research Foundation Inc

Arizona State University

Clive Henry Wasserfall

Mark A Atkinson

Alba Esther Morales

Tamir M Ellis

Joshua LaBaer

Benjamin George Keselowsky

Ji Qiu

Desmond A Schatz

Xiaofang Bian

Young Mee Yoon

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

Methods for diagnosis of type 1 diabetes

The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.

Materials and methods for modulating immune responses

Biomarkers that are diagnostic of type 1 diabetes, type 2 diabetes and/or diabetic disorder are identified. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of type 1 diabetes, type 2 diabetes and/or diabetic disorder. An analysis includes the parameters of matching for BMI and Tanner stage. Receiver-operator characteristic (ROC) curves were established to assess association of the biomarkers with a disease.

Biomarkers for differentiating between type 1 and type 2 diabetes

Growing community of inventors

Gainesville, FL, United States of America

Clive Henry Wasserfall